This comprehensive analysis discusses Alzheimer’s disease (AD), focusing on its growing prevalence, underlying pathologies, and current treatment strategies. The review highlights significant advances in AD therapies, particularly disease-modifying therapies (DMTs). Authors note the FDA’s conditional approval of aducanumab and lecanemab, monoclonal antibodies targeting amyloid plaques, marking a new era in AD treatment. Other therapeutic approaches include a focus on tau protein pathology, immunotherapy, and small molecule drugs. Emerging strategies involve targeting neuroinflammation and insulin resistance, as well as innovative approaches like stem cell therapy.

Non-pharmacological interventions are also emphasized, including cognitive and physical exercises, brain stimulation, and dietary modifications. The role of biomarkers in early detection and treatment is underscored, as early intervention is crucial for managing AD. Researchers summarize that, while significant strides have been made in understanding and treating AD, more research is needed, especially in early detection and more effective DMTs.

Reference: Buccellato FR, D’Anca M, Tartaglia GM, Del Fabbro M, Scarpini E, Galimberti D. Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies. Int J Mol Sci. 2023;24(18):13900. doi: 10.3390/ijms241813900.